

SUPPORT FOR THE AMENDMENTS

The amendments to Claims 1, 3, 4, 8, 11, and 12, and newly added Claims 40-52 are supported by the specification at pages 2-27. Support for the new Sequence Listing is found in on page 1, lines 5-8, which incorporates the priority document by reference. No new matter is believed to have been added to this application by these amendments.

REMARKS

Claims 1-4, 8-9, 11-13, 20-36, and 39-52 are pending. Favorable reconsideration is respectfully requested.

Applicants have now submitted a substitute Sequence Listing and a corresponding computer-readable Sequence Listing. The sequence information recorded in the corresponding computer-readable Sequence Listing is identical to the paper copy of the substitute Sequence Listing. Support for all of the sequences listed in the substitute Sequence Listing is found in the present application as originally filed. No new matter is believed to have been introduced by the submission of the substitute Sequence Listing and the corresponding computer-readable Sequence Listing.

The rejection under 35 U.S.C. §112, first paragraph, is believed to be obviated by the amendment submitted above. The claims discussed in the rejection have been canceled. Accordingly, withdrawal of this ground of rejection is respectfully requested.

The rejection under 35 U.S.C. §112, second paragraph, is believed to be obviated by the amendment submitted above in part and is, in part, respectfully traversed.

Applicants submit that the substitute Sequence Listing corrects the issues with respect to Claims 1-19 and 37-38.

Claims 5-7 have been canceled.

Regarding Claims 2 and 9, the present specification provides a detailed description that the claimed polynucleotide encodes a protein which regulates transcription of the LysR1 gene. See, for example, the text bridging pages 2 and 3. In view of this detailed description, one skilled in the art will readily appreciate the meaning of these claims.

Based on the foregoing, the claims are definite within the meaning of 35 U.S.C. §112, second paragraph. Accordingly, withdrawal of this ground of rejection is respectfully requested.

Applicants submit that the application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

James J. Kelly, Ph.D.
Registration No. 41,504



22850

(703) 413-3000
Fax No.: (703)413-2220
I:\atty\JK\203979US.AMD-2.wpd

IN THE SPECIFICATION

Please amend the specification as follows:

Page 33 (Abstract of the Disclosure), please replace the Sequence Listing filed on July 13, 2001 with the attached substitute Sequence Listing.

IN THE CLAIMS

- 1. (Amended) An isolated polynucleotide from *Corynebacterium* which encodes a protein comprising the amino acid sequence of SEQ ID NO:3 [2].
2. The isolated polynucleotide of Claim 1, wherein said protein has LysR1 transcriptional regulatory activity.
3. (Amended) An isolated polynucleotide, which comprises nucleotides 201 to 1109 of SEQ ID NO:1 and degenerates thereof.
4. (Amended) An isolated polynucleotide, which comprises the full complement of polynucleotide of SEQ ID NO: 1 nucleotides 201 to 1109 [which is complimentary to the polynucleotide of Claim 3].
8. (Amended) An isolated polynucleotide from *Corynebacterium glutamicum* which hybridizes under stringent conditions to the polynucleotide of Claim 3; wherein said stringent conditions comprise washing in 5X SSC at a temperature from 50 to 68°C.
9. The isolated polynucleotide of Claim 3, which encodes a protein having LysR1 transcriptional regulatory activity.

11. (Amended) An [The] isolated polynucleotide consisting of 15 to 383 consecutive nucleotides selected from SEQ ID NO: 1 [of Claim 10 which comprises SEQ ID NO:3].
12. A vector comprising the isolated polynucleotide of Claim 1.
13. A vector comprising the isolated polynucleotide of Claim 3.
20. A *Coryneform* bacterium which comprises an attenuated lysR1 gene.
21. (Amended) The *Coryneform* bacterium of Claim 20 [21], wherein said lysR1 gene comprises the polynucleotide sequence of SEQ ID NO:1.
22. *Escherichia Coli* DSM 13616.
23. A process for producing L-amino acids comprising culturing a bacterial cell in a medium suitable for producing L-amino acids, wherein said bacterial cell comprises an attenuated lysR1 gene.
24. The process of Claim 23, wherein said bacterial cell is a *Coryneform bacterium* or *Brevibacterium*.
25. The process of Claim 24, wherein said bacterial cell is selected from the group consisting of *Coryneform glutamicum*, *Corynebacterium acetoglutamicum*, *Corynebacterium acetoacidophilum*, *Corynebacterium melassecola*, *Corynebacterium thermoaminogenes*, *Brevibacterium flavum*, *Brevibacterium lactofermentum*, *Brevibacterium divaricatum*.
26. The process of Claim 23, wherein said lysR1 gene comprises the polynucleotide sequence of SEQ ID NO:1.
27. The process of Claim 23, wherein said L-amino acid is L-lysine.
28. The process of Claim 23, wherein said L-amino acid is L-valine.
29. The process of Claim 23, wherein said bacteria further comprises at least one gene whose expression is enhanced, wherein said gene is selected from the group consisting of *dapA*, *eno*, *zwf*, *pyc*, and *lysE*.

30. The process of Claim 23, wherein said bacteria further comprises at least one gene whose expression is attenuated, wherein said gene is selected from the group consisting of pck, pgi, and poxB.

31. A process for screening for polynucleotides which encode a protein having LysR1 transcriptional regulatory activity comprising hybridizing the isolated polynucleotide of Claim 1 to the polynucleotide to be screened; expressing the polynucleotide to produce a protein; and detecting the presence or absence of LysR1 transcriptional regulatory activity in said protein.

32. A process for screening for polynucleotides which encode a protein having LysR1 transcriptional regulatory activity comprising hybridizing the isolated polynucleotide of Claim 3 to the polynucleotide to be screened; expressing the polynucleotide to produce a protein; and detecting the presence or absence of LysR1 transcriptional regulatory activity in said protein.

33. A method for detecting a nucleic acid with at least 70% homology to nucleotide of Claim 1, comprising contacting a nucleic acid sample with a probe or primer comprising at least 15 consecutive nucleotides of the nucleotide sequence of Claim 1, or at least 15 consecutive nucleotides of the complement thereof.

34. A method for producing a nucleic acid with at least 70% homology to nucleotide of Claim 1, comprising contacting a nucleic acid sample with a primer comprising at least 15 consecutive nucleotides of the nucleotide sequence of Claim 1, or at least 15 consecutive nucleotides of the complement thereof.

35. A method for detecting a nucleic acid with at least 70% homology to nucleotide of Claim 3, comprising contacting a nucleic acid sample with a probe or primer comprising at

least 15 consecutive nucleotides of the nucleotide sequence of Claim 3, or at least 15 consecutive nucleotides of the complement thereof.

36. A method for producing a nucleic acid with at least 70% homology to nucleotide of Claim 3, comprising contacting a nucleic acid sample with a primer comprising at least 15 consecutive nucleotides of the nucleotide sequence of Claim 3, or at least 15 consecutive nucleotides of the complement thereof.

39. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2.--
Claims 40-52 (New)



SEQUENCE LISTING

<110> MOECKEL, BETTINA
 FARWICK, MIKE
 HERMANN, THOMAS
 KREUTZER, CAROLINE
 PFEFFERLE, WALTER

<120> NUCLEOTIDE SEQUENCES CODING FOR THE lysR1 GENE

<130> 203979US

<140> 09/903,770

<141> 2001-07-13

<160> 5 ..

<170> PatentIn version 3.1

<210> 1

<211> 1311

<212> DNA

<213> Corynebacterium glutamicum

<220>

<221> CDS

<222> (201)..(1109)

<223>

<400> 1

acagccccagg ggccgtttag gggaaaaagc tgcgttccaa tggcagcacc aaattgcagg 60

gataggggcg gg aacccatcac catcaacact gcagcggact gtttattcat gcccttgatt 120

attgccaaag aaacctttaa ggactagatc gaaaaacagc caactatagt taagtaatac 180

tgaacaattt tggaggtgtc gtg ctc aat ctc aac cgc tta cac atc ctg cag 233
 Val Leu Asn Leu Asn Arg Leu His Ile Leu Gln

1

5

10

gaa ttc cac cgc ctg gga acg att aca gca gtg gcg gaa tcc atg aac 281
 Glu Phe His Arg Leu Gly Thr Ile Thr Ala Val Ala Glu Ser Met Asn

15

20

25

tac agc cgc tct gcc atc tcc caa caa atg gcg ctg ctg gaa aaa gaa 329
 Tyr Ser Arg Ser Ala Ile Ser Gln Gln Met Ala Leu Leu Glu Lys Glu

30

35

40

att ggt gtg aaa ctc ttt gaa aaa agc ggc cga aac ctc tac ttc aca 377
 Ile Gly Val Lys Leu Phe Glu Lys Ser Gly Arg Asn Leu Tyr Phe Thr

45

50

55

gaa caa ggc gaa gtg ttg gcc tca gaa aca cat gcg atc atg gca gca 425
 Glu Gln Gly Glu Val Leu Ala Ser Glu Thr His Ala Ile Met Ala Ala

60

65

70

75

gtc gac cat gcc cgc gca gcc gtt cta gat tcg ctg tct gaa gtg tcc 473

Val Asp His Ala Arg Ala Ala Val Leu Asp Ser Leu Ser Glu Val Ser
 80 85 90

gga acg ctg aaa gtc acc tcc ttc caa tcc ctg ctg ttc acc ctt gcc 521
 Gly Thr Leu Lys Val Thr Ser Phe Gln Ser Leu Leu Phe Thr Leu Ala
 95 100 105

ccg aaa gcc atc gcg cgc ctg acc gag aaa tac cca cac ctg caa gta 569
 Pro Lys Ala Ile Ala Arg Leu Thr Glu Lys Tyr Pro His Leu Gln Val
 110 115 120

gaa atc tcc caa cta gaa gtc acc gca gcg ctc gaa gaa ctc cgc gcc 617
 Glu Ile Ser Gln Leu Glu Val Thr Ala Ala Leu Glu Glu Leu Arg Ala
 125 130 135

cgc cgc gtc gac gtc gca ctc ggc gag gaa tac ccc gtg gaa gtc ccc 665
 Arg Arg Val Asp Val Ala Leu Gly Glu Glu Tyr Pro Val Glu Val Pro
 140 145 150 155

ctt gtt gag gcc agc att cac cgc gaa gtc ctc ttc gaa gac ccc atg 713
 Leu Val Glu Ala Ser Ile His Arg Glu Val Leu Phe Glu Asp Pro Met
 160 165 170

ctg ctc gtc acc cca gca agc ggc cca tac tct ggc ctc acc ctg cca 761
 Leu Leu Val Thr Pro Ala Ser Gly Pro Tyr Ser Gly Leu Thr Leu Pro
 175 180 185

gaa ctc cgc gac atc ccc atc gcc atc gat cca ccc gac ctt ccc gcg 809
 Glu Leu Arg Asp Ile Pro Ile Ala Ile Asp Pro Pro Asp Leu Pro Ala
 190 195 200

ggc gaa tgg gtc cat agg ctc tgc cgg cgc gcc ggg ttt gag ccc cgc 857
 Gly Glu Trp Val His Arg Leu Cys Arg Arg Ala Gly Phe Glu Pro Arg
 205 210 215

gtg acc ttt gaa acc agc gat ccc atg ctc caa gca cac ctc gtg cgt 905
 Val Thr Phe Glu Thr Ser Asp Pro Met Leu Gln Ala His Leu Val Arg
 220 225 230 235

agc ggc ttg gcc gtg aca ttt tcc ccc aca ctg ctc acc ccg atg ctg 953
 Ser Gly Leu Ala Val Thr Phe Ser Pro Thr Leu Leu Thr Pro Met Leu
 240 245 250

gaa agc gtg cac atc cag ccg ctg ccc ggc aac ccc acg cgc acg ctc 1001
 Glu Ser Val His Ile Gln Pro Leu Pro Gly Asn Pro Thr Arg Thr Leu
 255 260 265

tac acc gcg gtc agg gaa ggg cgc cag ggg cat cca gcc att aaa gct 1049
 Tyr Thr Ala Val Arg Glu Gly Arg Gln Gly His Pro Ala Ile Lys Ala
 270 275 280

ttt cga cga gcc ctc gcc cat gtg gcc aaa gaa tct tat ttg gag gct 1097
 Phe Arg Arg Ala Leu Ala His Val Ala Lys Glu Ser Tyr Leu Glu Ala
 285 290 295

cgt cta gta gag tgagttttg tgaggcttca gacaaatcat cgcccaatgtac 1149
 Arg Leu Val Glu

300

tcgtcggtga ctgcggcgca cagtacgcgc agctgatcgc acgtcggtgc cgtgaggccg 1209
gcatctactc cgaagtcatc ccgcacacccg ccacccgaga cgatgtgcgc gctaaaaatg 1269
cagcagccct cgtccttcc ggtggcccat cctccgtgta tg 1311

<210> 2
<211> 303
<212> PRT
<213> *Corynebacterium glutamicum*

<400> 2

Val Leu Asn Leu Asn Arg Leu His Ile Leu Gln Glu Phe His Arg Leu
1 5 10 15

Gly Thr Ile Thr Ala Val Ala Glu Ser Met Asn Tyr Ser Arg Ser Ala
20 25 30

a' cut.
Ile Ser Gln Gln Met Ala Leu Leu Glu Lys Glu Ile Gly Val Lys Leu
35 40 45

Phe Glu Lys Ser Gly Arg Asn Leu Tyr Phe Thr Glu Gln Gly Glu Val
50 55 60

Leu Ala Ser Glu Thr His Ala Ile Met Ala Ala Val Asp His Ala Arg
65 70 75 80

Ala Ala Val Leu Asp Ser Leu Ser Glu Val Ser Gly Thr Leu Lys Val
85 90 95

Thr Ser Phe Gln Ser Leu Leu Phe Thr Leu Ala Pro Lys Ala Ile Ala
100 105 110

Arg Leu Thr Glu Lys Tyr Pro His Leu Gln Val Glu Ile Ser Gln Leu
115 120 125

Glu Val Thr Ala Ala Leu Glu Leu Arg Ala Arg Arg Val Asp Val
130 135 140

Ala Leu Gly Glu Glu Tyr Pro Val Glu Val Pro Leu Val Glu Ala Ser
145 150 155 160

Ile His Arg Glu Val Leu Phe Glu Asp Pro Met Leu Leu Val Thr Pro

165

170

175

Ala Ser Gly Pro Tyr Ser Gly Leu Thr Leu Pro Glu Leu Arg Asp Ile
180 185 190

Pro Ile Ala Ile Asp Pro Pro Asp Leu Pro Ala Gly Glu Trp Val His
195 200 205

Arg Leu Cys Arg Arg Ala Gly Phe Glu Pro Arg Val Thr Phe Glu Thr
210 215 220

Ser Asp Pro Met Leu Gln Ala His Leu Val Arg Ser Gly Leu Ala Val
225 230 235 240

Thr Phe Ser Pro Thr Leu Leu Thr Pro Met Leu Glu Ser Val His Ile
245 250 255

Gln Pro Leu Pro Gly Asn Pro Thr Arg Thr Leu Tyr Thr Ala Val Arg
260 265 270

a
out
Glu Gly Arg Gln Gly His Pro Ala Ile Lys Ala Phe Arg Arg Ala Leu
275 280 285

Ala His Val Ala Lys Glu Ser Tyr Leu Glu Ala Arg Leu Val Glu
290 295 300

<210> 3
<211> 383
<212> DNA
<213> Corynebacterium glutamicum

<400> 3
ttccaatccc tgctgttcac cttggcccg aaagccatcg cgccgcgtac cgagaaaatac 60
ccacacctgc aagttagaaat ctcccaacta gaagtcaccg cagcgctcga agaactccgc 120
gccccggcg tcgacgtcgc actcggcgag gaatacccg tggaaagtccc cttgttgag 180
gccagcattc accgcgaagt cctttcgaa gacccatgc tgctgtcact cccagcaagc 240
ggcccaatact ctggcctcac cctgccagaa ctccgcgaca tccccatcgc catcgatcca 300
cccgacattc cccgcggcgat atgggtccat aggctctgcc ggccgcgggg gtttgagccc 360
cgcgtgacct ttgaaaccag cga 383

<210> 4

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic DNA

<400> 4
ttccaatccc tgctgttcac

20

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic DNA

<400> 5
gtgacccttg aaaccagcga

20

*a'
cont.*